


**SOLE SOURCE JUSTIFICATION FOR
ACQUISITIONS UNDER THE SIMPLIFIED ACQUISITION THRESHOLD**

1. In accordance with Federal Acquisition Regulation 13.106-1(b)(1), I hereby determine that the requirement for a Service Agreement for TempO-Seq whole genome mouse assay services, with a period of performance from 6 January 2020 to 6 April 2020, listed on PR-ORD-19-02056 is available from only one source, and competition is precluded for the reasons indicated below. There are no substitutes available.
2. This acquisition is restricted to the following source:
Company: BioSpyder Technologies, Inc.
Company Address: 5922 Farnsworth Ct Ste 102, Carlsbad, CA, 92008
Company Point of Contact and Phone Number: Bitu Mavaddat, 760-476-1800
3. The Service Agreement for TempO-Seq whole genome mouse assay is estimated to cost \$19,250.00. It includes TempO-Sequence Whole-Genome Mouse Assay services under the BioSpyder platform. RNA in crude cell lysates will be analyzed, <10 nanograms, RNA needed for preparation of samples for amplification prior to sequencing on Nextseq.
4. Specific characteristics of the services provided by BioSpyder Technologies, Inc., limit the availability to a sole source. Only this suggested source can furnish the requirements, to the exclusion of other sources, because of the following:
 - a. This is a unique simplified quantitative analysis that is performed with specialized software and training which substantially reduces cost compared to whole genomic RNA sequencing. The Read depth >250 reads per gene target that provides cells lysates from 96 samples.
 - b. The Mouse Whole Genome Assay Services is only available from BioSpyder Technologies, Inc.,
5. Check and fill in all that are applicable:
☒ The material or service must be compatible in all aspects (form, fit, and function) with existing systems presently installed. This service has generated whole genome interrogation.
☐ A patent, copyright, proprietary data, or licensing agreement limits competition. The proprietary data are described as follows:
☒ These are "direct replacement" parts/components for existing equipment. These services are presently being used to support ongoing research projects, and, it is required for continuity of genomic RNA sequencing.
☒ Other information to support a sole-source buy:

- a. An intent to sole source notice (68HE0B20Q0026) was posted on FedConnect from 10/22/2019 to 11/01/2019 and no other vendors were identified.
- b. Market Research was conducted by the Contracting Officer to determine if there are any known contractors that can meet this requirement. A search on the internet and GSA Advantage indicated BioSpyder Technologies, Inc., does not have a GSA contract for this service and no other vendors were identified that could fulfill this requirement.
- c. Sole source and capability documentation were provided by BioSpyder Technologies, Inc.

CERTIFICATION

I certify that statements checked, and information provided above are complete and correct to the best of my knowledge. In accordance with FAR 13.106-1(b)(1). The facts of this acquisition preclude the use of full and open competition.



Cheri B. Taylor
Simplified Acquisition Contracting Officer

Date 5 Nov 19



Kathryn P. Barton, Chief
Simplified Acquisitions Branch

11/5/19
Date